Development of High-Protein-Producing Cell Lines from Hybridoma Clones Using Lentiviral Vectors
Abstract
The objective of this report is to present data resulting from a successfully created mammalian cell line expressing Bacillus anthracis monoclonal antibodies (Mabs), which was obtained using the Lentigen system (Lentigen Corp.; Gaithersburg, MD). The Lentigen protein manufacturing platform uses a novel vector system to rapidly generate cell lines capable of producing proteins. The LentiMax lentiviral gene delivery technology can stably deliver one or more nucleic acid sequences (that encode proteins) to a mammalian cell with up to 100 efficiency. Multiple protein-producing mammalian cell lines can be created in as little as four weeks because the LentiMax system allows nucleic acid sequences under 6 kb in length to be rapidly cloned. Transduction of cells with lentiviral particles is simple and allows for high copy numbers from the gene of interest. Lentigen Corp. has demonstrated that its LentiMax technology can produce clonal cells that express secreted proteins of interest to an excess of 10 g/L. This would dramatically reduce the cost to produce valuable proteins such as Mabs. Lentigen Corp. has received a Small Business Technology Transfer (STTR) Program grant to continue this work with the U.S. Army Combat Capabilities Development Command Chemical Biological Center (Aberdeen Proving Ground, MD).
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2020
- Accession Number
- AD1108384
Entities
People
- Boro Dropulic
- Darrel E. Menking
- James Carney
- James Valdes
- Lajos Baranyi
- Patricia E. Buckley
Organizations
- United States Army Combat Capabilities Development Command